CeriBell(NASDAQ) CBLL

CeriBell, Inc. makes brain monitoring tools for hospital patients. Its system helps doctors find seizures at the bedside quickly. This technology lets medical teams check brain health without waiting hours.

Tools for the Bedside

• Wearables: Disposable headbands used for a single patient; these generated $21.2 million in the three months ended June 30, 2026.
• Subscription Services: Monthly fees for using AI software and a portal; these brought in $6.9 million in the three months ended June 30, 2026.
• Ceribell System: Integrated platform including a portable recorder and AI algorithms to detect seizures and delirium.

Milestones in Brain Care

• Obtained FDA 510(k) clearance for the Delirium Monitor System in December 2025.
• Received FDA clearance for next-generation hardware and new neurology algorithms in June 2026.
• Deployed the monitoring platform to more than 700 hospitals as of June 30, 2026.
• Earned a CE Mark to support future expansion into European markets.

Why the System Stands Out

CeriBell uses artificial intelligence to interpret brain signals at the patient bedside. Medical teams can apply the portable hardware in minutes without waiting for specialists.

A Look at the Numbers

• Total revenue was $28.1 million in the three months ended June 30, 2026, up 33% year over year.
• Product revenue from headband sales grew 33% in the three months ended June 30, 2026.
• Net loss reached $39.0 million for the six-month period ended June 30, 2026.
• Cash and marketable securities totaled $129.3 million as of June 30, 2026.
• Adjusted EBITDA (non-GAAP) was a loss of $9.8 million for the three months ended June 30, 2026.

Bottom Line

CeriBell is growing its AI platform to replace slow, traditional brain monitoring in acute care. Its transition to a public company supports scaling its technology across hundreds of hospitals.